# Human Immunodeficiency Virus Type 1 (HIV-1) Infection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/human-immunodeficiency-virus-type-1-hiv-1-infection

> 4 upcoming FDA catalysts in human Immunodeficiency Virus Type 1 (HIV-1) Infection: isl (MRK) on Aug to Nov 2027 (topline data readout); isl (MRK) on August 2027 (primary completion); isl (MRK) on February 2029 (primary completion); isl (MRK) on Feb to May 2029 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug to Nov 2027 | [Isl topline data readout](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT06891066 (A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06891066)) |
| August 2027 | [Isl primary completion](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT06891066 (A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06891066)) |
| February 2029 | [Isl primary completion](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT07266831 (A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-02-01 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266831)) |
| Feb to May 2029 | [Isl topline data readout](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT07266831 (A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-02-01 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266831)) |

## Drugs

- [Isl](https://sec-api.dev/pdufa/isl) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/human-immunodeficiency-virus-type-1-hiv-1-infection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Human Immunodeficiency Virus Type 1 (HIV-1) Infection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/human-immunodeficiency-virus-type-1-hiv-1-infection

```bibtex
@misc{secapidev_indications_human_immunodeficiency_virus_type_1_hiv_1_infection_20261116,
  title        = {Human Immunodeficiency Virus Type 1 (HIV-1) Infection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/human-immunodeficiency-virus-type-1-hiv-1-infection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_human_immunodeficiency_virus_type_1_hiv_1_infection_20261116","title":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/human-immunodeficiency-virus-type-1-hiv-1-infection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
